Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Miami Beach, Florida Clinical Trials

A listing of Miami Beach, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (46) clinical trials

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent Resectable Osteosarcoma

Treatment will be administered in 28 day cycles with the first cycle in the neoadjuvant setting. This will be followed by surgery to render the participant in surgical remission. Subsequently the participant will continue to receive treatment for up to 12 additional cycles or until recurrence, whichever occurs first. For ...

Phase

4.56 miles

Learn More »

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

Phase

4.56 miles

Learn More »

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NOTE: Currently, this study is only open to nivolumab+daratumumab vs daratumumab monotherapy in multiple myeloma patients.

Phase

4.56 miles

Learn More »

Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.

Eighty (80) subjects fulfilling all inclusion/exclusion criteria's will be randomly assigned to receive allogeneic hMSCs or placebo in a 1:1 blinded fashion. Forty (40) subjects will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion. ...

Phase

4.56 miles

Learn More »

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

In this Study, cells administered via intravenous infusion (IV) will be tested in 37 patients in two phases (Pilot and Randomized): The pilot phase will consist of 12 subjects and the randomized phase will consist of 25 subjects. Subjects in each pilot phase group (Group 1, 2, 3 and 4) ...

Phase

4.56 miles

Learn More »

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

The investigators will perform a phase I/II placebo-controlled clinical trial in patients with HNSCC whose tumor has recurred, or secondary primary tumor is detected, post conventional radiotherapy with or without prior surgery or chemotherapy. For these patients, salvage surgery is the only standard curative therapeutic option, post-surgical recurrence rate is ...

Phase

4.56 miles

Learn More »

A Phase Ib/II Study Investigating the Safety Tolerability Pharmacokinetics and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated ...

Phase

4.56 miles

Learn More »

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

These agents may afford promote sustained immune regulation, reduce inflammation, and provide support for the residual beta cell mass. This integrated therapeutic regimen addresses major pathogenic mechanisms in T1D (Type 1 Diabetes) and thus represents a rational and well supported approach to preserve insulin secretion in T1D (Type 1 Diabetes). ...

Phase

4.56 miles

Learn More »

Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer

The purpose of this phase 1b (Phase 1/Phase 2) study is to assess the combination of a test drug (DS-8201a) with nivolumab in participants with HER2-expressing breast and urothelial cancer who had disease progression during or after prior therapies, did not respond to standard therapies, or for whom no standard ...

Phase

4.56 miles

Learn More »

A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

This study will enroll patients with intermediate or high risk myelodysplastic syndrome. All patients will receive at least 1 cycle of treatment (4 weeks). Patients with clinical benefit (CR,PR, or SD) then will undergo a second 4-week cycle of treatment. The primary objectives of this study are: Evaluate the safety ...

Phase

4.56 miles

Learn More »